Bloomberg: Vaccine Makers Can Skip U.S. Inspections

Bloomberg: Vaccine Makers Can Skip U.S. Inspections. “The U.S. Food and Drug Administration inspects a few thousand drug manufacturing plants every year to ensure their standards are up to par. Many of those inspections are required before a pharmaceutical company can gain approval of a new drug. They serve as a check on whether drugmakers can produce quality therapies. But that won’t be the case for Covid-19 vaccine developers that gain emergency authorization of a shot.”

Washington Post: Contamination at CDC lab delayed rollout of coronavirus tests

Washington Post: Contamination at CDC lab delayed rollout of coronavirus tests. “The failure by the Centers for Disease Control and Prevention to quickly produce a test kit for detecting the novel coronavirus was triggered by a glaring scientific breakdown at the CDC’s central laboratory complex in Atlanta, according to scientists with knowledge of the matter and a determination by federal regulators. The CDC facilities that assembled the kits violated sound manufacturing practices, resulting in contamination of one of the three test components used in the highly sensitive detection process, the scientists said.”